Standard BioTools(LAB) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Standard BioTools Reports Second Quarter 2024 Financial Results Delivered revenue of $37.2 million Accelerated merger synergies with$80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., July 31, 2024 -- Standard BioTools Inc. ("Standard BioTools" or the "C ...